- Forschung
- Karriere
- Aktuelles
- Institut
- Durchsuchen
- Spachumstellung
- Leichte Sprache
„”
The table provides an overview of all disclosed patent applications filed by the FVB for FMP technologies:
Title | Publication number | Applicant* | Status |
---|---|---|---|
Bifunctional peptide with mucoadhesive and virus binding properties | WO2023187142 | FUB, FVB | Published |
Novel FLT3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors | WO2023105087 | Tubulis, LMU, FVB, HZM | Published |
Conjugates comprising a Phosphorus (V) and a drug moiety | WO2023083900 | Tubulis, FVB | Licensed |
Thiol-Conjugation with Unsaturated Phosphorus (V) Compounds | WO2022223783 | FVB | Licensed |
MACC1-inhibitor for targeted therapy of MACC1-induced metastasis | WO2022223664 | MDC, Charité, FVB | Published |
Cellular uptake of Large Biomolecules enabled by Cell-surface-reactive cell-penetrating peptide additives | WO2022180242 | FVB | Published |
Improved CD30 targeting antibody drug conjugates and uses thereof | WO2022136555 | Tubulis, FVB, LMU | Licensed |
Inhibitors of NO production | WO2022043465 | MDC, FVB, Charité | Published |
1,2,4-triazole derivatives as tankyrase inhibitors | WO2019243822 | Oslo Univ Hospital, FVB, Univ Oulo | Published |
Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | WO2019234237 | FVB | Published |
Polyproline mimetics of proline-derived module-15 | WO2019162524 | FVB, Univ zu Köln | Licensed |
Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates | WO2019170710 | FVB, LMU | Licensed |
Selective inhibitors of genotoxic stress-induced IKK/NF-kB pathways | WO2018087389 | MDC, FVB | Published |
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates | WO2018041985 | FVB, LMU | Licensed |
Unusual substrates of tubulin tyrosine ligase | WO2017186855 | FVB, LMU | Licensed |
Antagonists of the thyroid-stimulating hormone receptor (TSHR) | WO2017186793 | FVB | Licensed |
Means and methods for site-specific functionalization of polypeptides | WO2016066749 | LMU, FVB | Licensed |
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | WO2016135199, WO2018019917 | FVB, MDC | Licensed |
Inhibitors for inhibiting tumor metastasis | WO2016092069 | FVB, Univ zu Köln | Licensed |
Structural mimetics of proline-rich peptides and use thereof | WO2013030111 | FVB, Univ zu Köln | Licensed |
Induction of alpha helix conformations in proteins and peptides | WO2011003626 | Univ zu Köln, FVB | Licensed |
Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists | WO2010047674 | US Health, FVB | Licensed |
Structural mimetics of proline-rich peptides and the pharmaceutical use thereof | WO2008040332 | FVB | Licensed |
*FUB - Freie Universität Berlin; FVB - Forschungsverbund Berlin e.V. (for its Leibniz-Forschungsinstitut für Molekulare Pharmakologie); LMU - Ludwig-Maximilians-Universität München; MDC - Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft; Oslo Univ Hospital - Oslo University Hospital HF; TUM - Technische Universität München; Univ Oulo - University of Oulo; Univ zu Köln - Universität zu Köln; US Health - The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services; WWU - Westfälische Wilhelms-Universität Münster